- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01290900
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
August 31, 2017 updated by: Pfizer
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
This is a single dose study in healthy male volunteers to investigate the effect of high doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Provision of signed informed consent prior to any study specific procedures
- Healthy male volunteers aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venepuncture
- Have a body mass index (BMI) between 19 and 30 kg/m2 and a body weight between 60 and 100 kg
- Be a non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for more than 3 months prior to the start of the study
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
- Any clinically significant abnormalities in physical examination, clinical chemistry, haematology or urinalysis results as judged by the Investigator
- Abnormal vital signs, after 10 minutes supine rest, defined as any of the following: Systolic blood pressure (SBP) greater than 140 mmHg, Diastolic blood pressure (DBP) greater than 90 mmHg, Heart rate less than 40 or greater than 85 beats per minute - at Visit 1
- Prolonged QTcF >450 ms or shortened QTcF <340 ms
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This includes volunteers with any of the following: Clinically significant PR (PQ) interval prolongation, Intermittent second or third degree AV block (Mobitz II type 1, Wenchebach during sleep is not disqualifying), Incomplete, full or intermittent bundle branch block (QRS less than 110 ms with normal QRS and T wave morphology is acceptable if there is no evidence of left ventricular hypertrophy), Abnormal T wave morphology, particularly in the protocol defined primary lead
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CXL104
2000 mg NXL104 + 1500 mg Ceftaroline (IV)
|
IV Solution
IV Solution
|
Experimental: CAZ104
Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
|
IV Solution
IV Saline
IV Solution
|
Active Comparator: Moxifloxacin
Moxifloxacin 400mg (1 tablet)
|
Tablet (1)
|
Placebo Comparator: Placebo
Placebo Infusion (saline)
|
IV Saline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG will be performed pre-dose
|
12-lead dECG will be performed pre-dose
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 30 min after starting dosing.
|
12-lead dECG at 30 min after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 60 min after starting dosing.
|
12-lead dECG at 60 min after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 90 min after starting dosing.
|
12-lead dECG at 90 min after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 2 hour after starting dosing.
|
12-lead dECG at 2 hour after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 3 hour after starting dosing.
|
12-lead dECG at 3 hour after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 4 hour after starting dosing.
|
12-lead dECG at 4 hour after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 6 hour after starting dosing.
|
12-lead dECG at 6 hour after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 8 hour after starting dosing.
|
12-lead dECG at 8 hour after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 12 hour after starting dosing.
|
12-lead dECG at 12 hour after starting dosing.
|
To investigate the effect of supratherapeutic doses of ceftazidime NXL104 (CAZ104) or ceftaroline fosamil NXL104 (CXL104) on the QT interval (QTcF).
Time Frame: 12-lead dECG at 24 hour after starting dosing.
|
12-lead dECG at 24 hour after starting dosing.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG will be performed pre-dose
|
12-lead dECG will be performed pre-dose
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 30 min after starting dosing.
|
12-lead dECG at 30 min after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 60 min after starting dosing.
|
12-lead dECG at 60 min after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 90 min after starting dosing.
|
12-lead dECG at 90 min after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 2 hour after starting dosing.
|
12-lead dECG at 2 hour after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 3 hour after starting dosing.
|
12-lead dECG at 3 hour after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 4 hour after starting dosing.
|
12-lead dECG at 4 hour after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 6 hour after starting dosing.
|
12-lead dECG at 6 hour after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 8 hour after starting dosing.
|
12-lead dECG at 8 hour after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 12 hour after starting dosing.
|
12-lead dECG at 12 hour after starting dosing.
|
To investigate the effect of CAZ104 and CXL104, on additional ECG variables (heart rate, RR, PR, QRS, QT, and QTcB).
Time Frame: 12-lead dECG at 24 hour after starting dosing.
|
12-lead dECG at 24 hour after starting dosing.
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken pre-dose
|
Blood samples will be taken pre-dose
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 30 min after starting dosing
|
Blood samples will be taken at 30 min after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 60 min after starting dosing
|
Blood samples will be taken at 60 min after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 75 min after starting dosing
|
Blood samples will be taken at 75 min after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 90 min after starting dosing
|
Blood samples will be taken at 90 min after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 2 hour after starting dosing
|
Blood samples will be taken at 2 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 3 hour after starting dosing
|
Blood samples will be taken at 3 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 4 hour after starting dosing
|
Blood samples will be taken at 4 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 6 hour after starting dosing
|
Blood samples will be taken at 6 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 8 hour after starting dosing
|
Blood samples will be taken at 8 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 12 hour after starting dosing
|
Blood samples will be taken at 12 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 18 hour after starting dosing
|
Blood samples will be taken at 18 hour after starting dosing
|
To assess the PK of NXL104, ceftaroline, ceftazidime and moxifloxacin by determination where applicable of Cmax, tmax, AUC(0-t), AUC, t½, CL, CL/F, Vss, and Vz/F.
Time Frame: Blood samples will be taken at 24 hour after starting dosing.
|
Blood samples will be taken at 24 hour after starting dosing.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: David Mathews, MD, Quintiles, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
February 4, 2011
First Submitted That Met QC Criteria
February 4, 2011
First Posted (Estimate)
February 7, 2011
Study Record Updates
Last Update Posted (Actual)
September 1, 2017
Last Update Submitted That Met QC Criteria
August 31, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D4280C00007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Volunteers
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
PMV Pharmaceuticals, IncCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.UnknownHealthy Male VolunteersKorea, Republic of
-
Bristol-Myers SquibbCompletedHealthy Male VolunteersUnited States
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthy Male VolunteersKorea, Republic of
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Allist Pharmaceuticals, Inc.CompletedHealthy Male VolunteersChina
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
Clinical Trials on NXL104
-
Forest LaboratoriesCompletedUrinary Tract InfectionsRussian Federation, Bulgaria, Poland, Germany, United States, Lebanon, Turkey
-
PfizerCompletedHealthyUnited Kingdom
-
PfizerCompletedHealthy Male and Female Japanese VolunteersUnited States
-
PfizerCompletedComplicated Urinary Tract InfectionUnited States, Lebanon, Jordan
-
PfizerCompletedComplicated Intra-abdominal InfectionsUnited States, Lebanon, France, Romania, Bulgaria, India, Poland, Russian Federation